Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Shares Outstanding (2023 - 2025)

Immunome (IMNM) has disclosed Shares Outstanding for 3 consecutive years, with $113.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 75.51% year-over-year to $113.1 million, compared with a TTM value of $113.1 million through Dec 2025, up 75.51%, and an annual FY2025 reading of $113.1 million, up 75.51% over the prior year.
  • Shares Outstanding was $113.1 million for Q4 2025 at Immunome, up from $91.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $113.1 million in Q4 2025 and bottomed at $12.2 million in Q1 2023.
  • Average Shares Outstanding over 3 years is $58.6 million, with a median of $60.2 million recorded in 2024.
  • The sharpest move saw Shares Outstanding surged 395.16% in 2024, then soared 44.99% in 2025.
  • Year by year, Shares Outstanding stood at $43.3 million in 2023, then skyrocketed by 49.04% to $64.5 million in 2024, then soared by 75.51% to $113.1 million in 2025.
  • Business Quant data shows Shares Outstanding for IMNM at $113.1 million in Q4 2025, $91.7 million in Q3 2025, and $87.0 million in Q2 2025.